U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C48H38F8N8O8S4
Molecular Weight 1135.111
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of REDAPORFIN

SMILES

CNS(=O)(=O)C1=CC=C(F)C(=C1F)C2=C3CCC(=N3)C(=C4NC(C=C4)=C(C5=NC(CC5)=C(C6=CC=C2N6)C7=C(F)C(=CC=C7F)S(=O)(=O)NC)C8=C(F)C(=CC=C8F)S(=O)(=O)NC)C9=C(F)C(=CC=C9F)S(=O)(=O)NC

InChI

InChIKey=CKRVBMUJCFKRND-ZXWMLXKTSA-N
InChI=1S/C48H38F8N8O8S4/c1-57-73(65,66)33-17-5-21(49)37(45(33)53)41-25-9-11-27(61-25)42(38-22(50)6-18-34(46(38)54)74(67,68)58-2)29-13-15-31(63-29)44(40-24(52)8-20-36(48(40)56)76(71,72)60-4)32-16-14-30(64-32)43(28-12-10-26(41)62-28)39-23(51)7-19-35(47(39)55)75(69,70)59-3/h5-9,11,14,16-20,57-61,64H,10,12-13,15H2,1-4H3/b41-25+,41-26+,42-27+,42-29+,43-28+,43-30+,44-31+,44-32+

HIDE SMILES / InChI

Molecular Formula C48H38F8N8O8S4
Molecular Weight 1135.111
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Approval Year

Substance Class Chemical
Created
by admin
on Sat Dec 16 11:25:06 UTC 2023
Edited
by admin
on Sat Dec 16 11:25:06 UTC 2023
Record UNII
ZP3QP1H44W
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
REDAPORFIN
INN   WHO-DD  
INN  
Official Name English
3,3',3'',3'''-(7,8,17,18-TETRAHYDROPORPHYRIN-5,10,15,20-TETRAYL)TETRAKIS(2,4-DIFLUORO-N-METHYLBENZENESULFONAMIDE)
Systematic Name English
BENZENESULFONAMIDE, 3,3',3'',3'''-(7,8,17,18-TETRAHYDRO-21H,23H-PORPHINE-5,10,15,20-TETRAYL)TETRAKIS(2,4-DIFLUORO-N-METHYL-
Systematic Name English
Redaporfin [WHO-DD]
Common Name English
F2BMET
Common Name English
redaporfin [INN]
Common Name English
LUZ-11
Code English
Classification Tree Code System Code
EU-Orphan Drug EU/3/15/1470
Created by admin on Sat Dec 16 11:25:06 UTC 2023 , Edited by admin on Sat Dec 16 11:25:06 UTC 2023
FDA ORPHAN DRUG 556616
Created by admin on Sat Dec 16 11:25:06 UTC 2023 , Edited by admin on Sat Dec 16 11:25:06 UTC 2023
Code System Code Type Description
FDA UNII
ZP3QP1H44W
Created by admin on Sat Dec 16 11:25:06 UTC 2023 , Edited by admin on Sat Dec 16 11:25:06 UTC 2023
PRIMARY
SMS_ID
100000183241
Created by admin on Sat Dec 16 11:25:06 UTC 2023 , Edited by admin on Sat Dec 16 11:25:06 UTC 2023
PRIMARY
INN
10170
Created by admin on Sat Dec 16 11:25:06 UTC 2023 , Edited by admin on Sat Dec 16 11:25:06 UTC 2023
PRIMARY
PUBCHEM
86287614
Created by admin on Sat Dec 16 11:25:06 UTC 2023 , Edited by admin on Sat Dec 16 11:25:06 UTC 2023
PRIMARY
CAS
1224104-08-8
Created by admin on Sat Dec 16 11:25:06 UTC 2023 , Edited by admin on Sat Dec 16 11:25:06 UTC 2023
PRIMARY
NCI_THESAURUS
C114382
Created by admin on Sat Dec 16 11:25:06 UTC 2023 , Edited by admin on Sat Dec 16 11:25:06 UTC 2023
PRIMARY
EVMPD
SUB197619
Created by admin on Sat Dec 16 11:25:06 UTC 2023 , Edited by admin on Sat Dec 16 11:25:06 UTC 2023
PRIMARY
Related Record Type Details
ACTIVE MOIETY
Originator: Bluepharma, Universidade de Coimbra; Developer: Luzitin; Class: Antineoplastic, Macrocyclic compound, Porphyrin; Mechanism of Action: Photosensitiser; Orphan Drug Status: No; On Fast track: No; New Molecular Entity: Yes; Available For Licensing: Yes; Highest Development Phase: Phase II for Head and neck cancer; Most Recent Events: 15 Mar 2016 Phase-II clinical trials in Head and neck cancer in Portugal (IV), 20 Feb 2014 Phase-I/II clinical trials in Head and neck cancer in Portugal (IV), 08 Dec 2012 Luzitin licensed patents by Bluepharma and Universidade de Coimbra